Summit Therapeutics Inc. (SMMT) Cash Flow Statement
Summit Therapeutics Inc. (SMMT) generated -$458.4M of operating cash flow over the twelve months to 2026-06-30, spent $1.4M on capital expenditure and had free cash flow of -$459.8M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SMMTSummit Therapeutics Inc.Follow SMMT — free
—
Price chart with a free account
- Market cap
- 12.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 17 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -48.1 | -72.6 | -41.6 | -76.8 | -142.1 | -322.9 | -458.4 | |
| Capital expenditure | 0.4 | 0.3 | 0.6 | 0.1 | 0.1 | 0.7 | -1.4 | |
| Free cash flow | -48.5 | -72.9 | -42.2 | -76.9 | -142.2 | -323.6 | -459.8 | |
| Dividends paid | 0.0 | — | — | — | — | — | — | |
| Stock-based compensation | 1.8 | 12.8 | 11.9 | 14.1 | 51.0 | 732.4 | — |
USD millions · SEC XBRL
Summit Therapeutics Inc. — questions
- What is Summit Therapeutics Inc.'s operating cash flow?
- -$458.4M over the twelve months to 2026-06-30.
- How much does Summit Therapeutics Inc. spend on capital expenditure?
- $1.4M over the twelve months to 2026-06-30.
- What is Summit Therapeutics Inc.'s free cash flow?
- -$459.8M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Summit Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.